Management of Stage IIIA (N2) Non-Small Cell Lung Cancer

被引：19
|
作者：
Gillaspie, Erin A. [1 ]
Wigle, Dennis A. [1 ]
机构：
[1] Mayo Clin, Div Thorac Surg, 200 First St, Rochester, MN 55905 USA
来源：
THORACIC SURGERY CLINICS | 2016年 / 26卷 / 03期
关键词：
Stage IIIA; Non-small cell lung cancer; PORT; Adjuvant; Neoadjuvant; Surgery; N2; TRIALIST ASSOCIATION ANITA; POSTOPERATIVE RADIOTHERAPY; ADJUVANT CHEMOTHERAPY; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; RANDOMIZED-TRIAL; NEOADJUVANT THERAPY; SURGICAL RESECTION; DOSE RADIATION;
D O I：
10.1016/j.thorsurg.2016.04.001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
There is no consensus as to the optimal management of IIIA (N2) non-small cell lung cancer, nor for the role of surgery in treating this disease stage. Clinical trial evidence struggles to keep up with technology advancement and the evolution of expert opinion. Despite advances in chemotherapeutic regimens, methods of delivery for radiation, and less invasive surgical techniques, survival for patients with stage IIIA-N2 malignancies remains poor. Further developments in both will stimulate and maintain controversy in the field for years to come.
引用
收藏
页码：271 / +
页数：17
相关论文
共 50 条
  • [21] Tumor Microenvironment and Brain Metastases in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
    Zhang, Qin
    Fu, Xiaolong
    Cai, Xuwei
    Feng, Wen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S372 - S372
  • [22] Risk Factors of Brain Metastases in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
    Zhang, Qin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S622 - S622
  • [23] A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small cell lung cancer
    Takamori, S
    Rikimaru, T
    Hayashi, A
    Tayama, K
    Mitsuoka, M
    Fujimoto, K
    Horiuchi, M
    Hayabuchi, N
    Oizumi, K
    Shirouzu, K
    LUNG CANCER, 2000, 29 (01) : 49 - 56
  • [24] Accuracy Of Contemporary Pet/ct Scans In Assessing Stage Iiia (n2) Non-Small Cell Lung Cancer
    Genchanok, Y.
    Nemesure, B.
    Moore, W.
    Matthews, R.
    Bilfinger, T. V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [25] Survival determinants in patients with stage IIIa, N2 non-small cell lung cancer underwent complete resection
    Takizawa, T
    Terashima, M
    Koike, T
    Aoki, T
    2ND INTERNATIONAL CONGRESS ON LUNG CANCER, 1996, : 375 - 379
  • [26] Skip mediastinal nodal metastases in the IIIA/N2 non-small cell lung cancer
    Ilic, N
    Petricevic, A
    Tanfara, S
    Kotarac, S
    Arar, D
    Mise, K
    Ilic, NF
    Banovic, J
    LUNG CANCER, 2005, 49 : S281 - S281
  • [27] Skip mediastinal nodal metastases in the IIIA/N2 non-small cell lung cancer
    Illic, N.
    Petricevic, A.
    Arar, D.
    Kotarac, S.
    Banovic, J.
    Frieta Ilic, N.
    Tripkovic, A.
    Ercegovic, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 328 - 328
  • [28] Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer
    De Marinis, Filippo
    Gebbia, V.
    De Petris, L.
    ANNALS OF ONCOLOGY, 2005, 16 : 116 - 122
  • [29] Role of surgery for stage IIIA-N2 non-small cell lung cancer
    Yang, Fan
    Wang, Jun
    THORACIC CANCER, 2011, 2 (03) : 90 - 94
  • [30] Is Salvage Lung Resection Necessary After Definitive Chemoradiation Therapy for Stage IIIA(N2) Non-Small Cell Lung Cancer?
    Turna, A.
    Melek, H.
    Agkoc, M.
    Gebitekin, C.
    Turna, H.
    Dincbas, F.
    Erturan, S.
    Aydin, G.
    Kaynak, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1105 - S1106
12345